» Articles » PMID: 21485675

Analysis of Human Cultured Myotubes Responses Mediated by Ryanodine Receptor 1

Overview
Publisher Sage Publications
Date 2011 Apr 14
PMID 21485675
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant hyperthermia is a life-threatening condition caused by autosomal dominant mutations in the ryanodine receptor type 1 gene. Identifying patients predisposed to malignant hyperthermia is done through the Ca-induced Ca release test in Japan. We examined the intracellular calcium concentration in human cultured muscle cells and compared the sensitivity of myotubes to ryanodine receptor type 1 activators based on the Ca-induced Ca release rate. We assessed the utility of this method as an identifying test for predisposition to malignant hyperthermia. Muscle specimens were obtained from 34 individuals undergoing the Ca-induced Ca release test. We cultured myotubes from residual material and monitored changes in intracellular calcium concentration after exposure to the ryanodine receptor type 1 activators caffeine, halothane and 4-chloro-m-cresol by measuring fura-2 fluorescence. We determined the half maximal effective concentrations (EC50) for the test compounds in each myotube and calculated cut-off points using receiver operating characteristic curves. Seventeen patients each were classified into the accelerated and non-accelerated groups based on their Ca-induced Ca release rate. The EC50 values for caffeine, halothane and 4-chloro-m-cresol of the accelerated group were significant lower than those of the non-accelerated group (P < 0.001, P < 0.001 and P < 0.001, respectively). The calculated cut-off points of EC50 values for caffeine, halothane and 4-CmC were 3.62 mM, 2.28 mM and 197 microM, respectively. An increased sensitivity to ryanodine receptor type 1 activators was seen in myotubes in the accelerated group. This functional test on human cultured myotubes indicates that the alteration of their intracellular Ca2+ homeostasis may identify the predisposition to malignant hyperthermia.

Citing Articles

Effects of Remimazolam on Intracellular Calcium Dynamics in Myotubes Derived from Patients with Malignant Hyperthermia and Functional Analysis of Type 1 Ryanodine Receptor Gene Variants.

Miyoshi H, Otsuki S, Mukaida K, Kido K, Sumii A, Ikeda T Genes (Basel). 2023; 14(11).

PMID: 38002952 PMC: 10671487. DOI: 10.3390/genes14112009.


Distinct pathophysiological characteristics in developing muscle from patients susceptible to malignant hyperthermia.

Figueroa L, Kraeva N, Manno C, Ibarra-Moreno C, Tammineni E, Riazi S Br J Anaesth. 2023; 131(1):47-55.

PMID: 36792386 PMC: 10308439. DOI: 10.1016/j.bja.2023.01.008.


Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Lawal T, Wires E, Terry N, Dowling J, Todd J Orphanet J Rare Dis. 2020; 15(1):113.

PMID: 32381029 PMC: 7204063. DOI: 10.1186/s13023-020-01384-x.


Myotoxicity of local anesthetics is equivalent in individuals with and without predisposition to malignant hyperthermia.

Otsuki S, Yasuda T, Mukaida K, Noda Y, Kanzaki R, Miyoshi H J Anesth. 2018; 32(4):616-623.

PMID: 29938387 DOI: 10.1007/s00540-018-2526-4.


Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.

Kondo T, Yasuda T, Mukaida K, Otsuki S, Kanzaki R, Miyoshi H J Anesth. 2018; 32(2):174-181.

PMID: 29344738 DOI: 10.1007/s00540-018-2451-6.